peptide backbone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-07. Anything still debated is marked as such rather than presented as settled.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Retinal dystrophy (cone-rod dystrophy) in all cases, usually within a few weeks of birth and progressively worsening until about 20 years of age when vision is lost. Nystagmus (often one of the first symptoms identified) and photophobia are also very common. Mild to moderate progressive bilateral sensorineural hearing loss. Hearing impairment is typically diagnosed between the ages of 1 and 10. Congestive heart failure (dilated cardiomyopathy) in over 60% of individuals over the course of their lifetimes. Around 40% of individuals suffer from a severe cardiomyopathy within the first few months of life. For those who survive, cardiomyopathy occurs in 1 of 5 patients with onset in adolescence or adulthood. Hypothyroidism tends to occur in less than half of patients. Growth hormone dysfunction is common in around half of individuals with AS. Thoracic and lumbar scoliosis, kyphosis, or lordosis is present in around 68% of patients. Male hypergonadotropic and hypogonadotropic hypogonadism and female hyperandrogenism. Men can experience microphallus, undescended testes, hypospadias, small testes, and gynecomastia. They are also unlikely to be fertile. Women can experience hirsutism, alopecia, oligomenorrhea/amenorrhea, polycystic ovaries, high testosterone levels, abnormal breast development, precocious puberty, and endometriosis. Female fertility is unlikely and only reported in a few cases. Childhood obesity occurs in most people with AS. Alström infants are usually within the normal birth weight and then experience rapid weight gain within the first 2–36 months.
It controls trunk muscles and part of the sympathetic nervous system. Tonic receptor A sensory receptor that continues to fire throughout the duration of a stimulus. Contrasts with phasic receptors, which adapt quickly. Tonic-clonic seizure A type of generalized seizure involving an initial tonic phase of muscle stiffening followed by a clonic phase of rhythmic jerking. Often accompanied by loss of consciousness. Top-down processing Perception driven by cognition — the brain applies what it knows and expects to what it sees. In contrast to bottom-up processing. Transcranial direct current stimulation (tDCS) A noninvasive brain stimulation technique that applies a low electrical current to the scalp to modulate neuronal excitability. Transcranial magnetic stimulation (TMS) A noninvasive method to stimulate or inhibit brain activity using magnetic fields. Used in both research and treatment for depression and other disorders. Transduction The process of converting a physical stimulus (e.g., light, sound, touch) into an electrical signal in sensory receptors. Trigeminal nerve (Cranial Nerve V) The largest cranial nerve, responsible for sensation in the face and motor control of biting and chewing. Trophic factor A substance, such as nerve growth factor (NGF), that supports the growth, survival, and differentiation of neurons. Tuberomammillary nucleus A small cluster of histaminergic neurons in the hypothalamus involved in arousal, attention, and the sleep–wake cycle. Two-point discrimination The ability to distinguish two closely spaced tactile stimuli as separate.
=== Craniofacial syndromes === Of substantial recent interest is the idea that there is a general human tendency towards developing short lower jaws (neoteny) is a major cause of OSA through a combined condition called glossoptosis. The posterior "normal" tongue is displaced backwards by a smaller "abnormal" anterior tongue and lower jaw. In much the same way, a narrow upper jaw will also contribute to OSA due to its relation to airway volume. A narrower upper jaw results in narrower nasal passages and a narrower throat; this also appears to be why so many OSA patients experience nasal congestion, especially while lying down. Maxillofacial surgeons see many effects of small lower jaws, including crowded teeth, malocclusions, as well as OSA – all of which are treatable by surgical operations that increase and normalise jaw size. Operations such as custom BIMAX, GenioPaully, and IMDO (in adolescence) offer a valid medical option that replaces all traditional forms of OSA treatment – including CPAP, Mandibular Advancement Splints, tonsillectomy, and UPPP. There are patterns of unusual facial features that occur in recognizable syndromes. Some of these craniofacial syndromes are genetic, and others are from unknown causes. In many craniofacial syndromes, unusual features involve the nose, mouth, and jaw, or resting muscle tone, and put the individual at risk for OSA. Down syndrome is one such syndrome. In this chromosomal abnormality, several features combine to make the presence of obstructive sleep apnea more likely.
== Signs and symptoms == In their early stages, soft-tissue sarcomas usually do not cause symptoms. Because soft tissue is relatively elastic, tumors can grow rather large, pushing aside normal tissue, before they are felt or cause any problems. The first noticeable symptom is usually a painless lump or swelling. As the tumor grows, it may cause other symptoms, such as pain or soreness, as it presses against nearby nerves and muscles. If in the abdomen it can cause abdominal pains commonly mistaken for menstrual cramps, indigestion, or cause constipation.
Once the magnetic particles are functionalized, they are dispersed in a cell mixture where they bind to only the cells of interest. The resulting cell/particle mixture can then be flowed through a microfluidic device with a magnetic field to separate the targeted cells from the rest. Conversely, microfluidic-assisted magnetophoresis may be used to facilitate efficient mixing within microdroplets or plugs. To accomplish this, microdroplets are injected with paramagnetic nanoparticles and are flowed through a straight channel which passes through rapidly alternating magnetic fields. This causes the magnetic particles to be quickly pushed from side to side within the droplet and results in the mixing of the microdroplet contents. This eliminates the need for tedious engineering considerations that are necessary for traditional, channel-based droplet mixing. Other research has also shown that the label-free separation of cells may be possible by suspending cells in a paramagnetic fluid and taking advantage of the magneto-Archimedes effect. While this does eliminate the complexity of particle functionalization, more research is needed to fully understand the magneto-Archimedes phenomenon and how it can be used to this end. This is not an exhaustive list of the various applications of microfluidic-assisted magnetophoresis; the above examples merely highlight the versatility of this separation technique in both current and future applications.
Sources: en.wikipedia.org
== Structure == Alpha 2-antiplasmin (α2AP) is a member of the serine protease inhibitor (serpin) superfamily and is structurally characterized by a central serpin domain flanked by unique N- and C-terminal extensions. The mature human α2AP protein consists of 452 amino acids, with a 12-residue N-terminus, a central serpin domain, and a C-terminal tail of approximately 55 residues. The reactive center loop, which is crucial for its inhibitory function, protrudes from the central serpin domain and contains the Arg364-Met365 peptide bond that is specifically targeted and cleaved by plasmin. There are two main circulating forms: Met-α2AP, which has methionine at the N-terminus, and Asn-α2AP, which is N-terminally shortened and starts with asparagine; the latter form constitutes about 70% of plasma α2AP and is more efficiently cross-linked to fibrin. The C-terminal region, rich in lysine residues, mediates the initial non-covalent binding to plasmin, facilitating the formation of a stable 1:1 stoichiometric complex. This structural arrangement allows α2AP to efficiently interact with plasmin and be incorporated into fibrin clots via cross-linking by factor XIIIa.
nylon-flock workers workers who spray prints onto textiles with polyamide-amine dyes battery workers who are exposed to thionyl chloride workers at plants that use or manufacture diacetyl Diacetyl is a chemical used to produce the artificial butter flavoring in many foods such as candy and microwave popcorn and occurring naturally in wines. This first came to public attention when eight former employees of the Gilster-Mary Lee popcorn plant in Jasper, Missouri developed bronchiolitis obliterans. Due to this event, bronchiolitis obliterans began to be referred to in the popular media as "popcorn lung" or "popcorn workers lung". It is also referred to as "flavorings-related lung disease".
Every mRNA consists of three parts: a 5′ untranslated region (5′UTR), a protein-coding region or open reading frame (ORF), and a 3′ untranslated region (3′UTR). The coding region carries information for protein synthesis encoded by the genetic code to form triplets. Each triplet of nucleotides of the coding region is called a codon and corresponds to a binding site complementary to an anticodon triplet in transfer RNA. Transfer RNAs with the same anticodon sequence always carry an identical type of amino acid. Amino acids are then chained together by the ribosome according to the order of triplets in the coding region. The ribosome helps transfer RNA to bind to messenger RNA and takes the amino acid from each transfer RNA and makes a structure-less protein out of it. Each mRNA molecule is translated into many protein molecules, on average ~2800 in mammals. In prokaryotes translation generally occurs at the point of transcription (co-transcriptionally), often using a messenger RNA that is still in the process of being created. In eukaryotes translation can occur in a variety of regions of the cell depending on where the protein being written is supposed to be. Major locations are the cytoplasm for soluble cytoplasmic proteins and the membrane of the endoplasmic reticulum for proteins that are for export from the cell or insertion into a cell membrane. Proteins that are supposed to be produced at the endoplasmic reticulum are recognised part-way through the translation process.
=== P granules === Another example of liquid droplets in cells are the germline P granules in Caenorhabditis elegans. These granules separate out from the cytoplasm and form droplets, as oil does from water. Both the granules and the surrounding cytoplasm are liquid in the sense that they flow in response to forces, and two of the granules can coalesce when they come in contact. When (some of) the molecules in the granules are studied (via fluorescence recovery after photobleaching), they are found to rapidly turnover in the droplets, meaning that molecules diffuse into and out of the granules, just as expected in a liquid droplet. The droplets can also grow to be many molecules across (micrometres) Studies of droplets of the Caenorhabditis elegans protein LAF-1 in vitro also show liquid-like behaviour, with an apparent viscosity
=== Research tool === Due to its high proteolytic specificity, thrombin is a valuable biochemical tool. The thrombin cleavage site (Leu-Val-Pro-Arg-Gly-Ser) is commonly included in linker regions of recombinant fusion protein constructs. Following purification of the fusion protein, thrombin can be used to selectively cleave between the arginine and glycine residues of the cleavage site, effectively removing the purification tag from the protein of interest with a high degree of specificity.
Sources: en.wikipedia.org
In early 2008, Bush vowed full support for admitting Ukraine and Georgia into NATO despite Russia's opposition to the further enlargement of NATO. During the 2008 Russo-Georgian diplomatic crisis, Bush condemned Russia for recognizing the separatist government of South Ossetia. When Russian troops invaded Georgia later that summer, Bush said: "Bullying and intimidation are not acceptable ways to conduct foreign policy in the 21st century."
Given the reference range for serum potassium is 3.5-5.5 mEq/L, concentrations up to 8 mEq/L shorten action potential duration and the refractory period due to an allosteric effect of potassium ions on potassium channels, leading to increased conduction velocity and subsequently quicker potassium efflux, which contributes to quicker repolarization and the mentioned shortening of the refractory period. At approximately 8 mEq/L and beyond, the shortened refractory period and increased resting membrane potential diminish the quantity of voltage-gated sodium channels ready to contribute to rapid phase 0 depolarization due to the inactivation gate requiring further repolarization to open back up. At potassium concentrations beyond 14mEq/L, enough sodium channels remain inactivated to no longer generate an action potential, ultimately leading to no heartbeat. Heart potassium levels after lethal injection can reach 160.0 mEq/L. Depolarizing the muscle cell inhibits its ability to fire by reducing the available number of sodium channels (they are placed in an inactivated state). ECG changes vary depending on serum potassium concentrations and on the individual. Peaked T-waves signifying faster repolarization and potentially instances of early repolarization and phase 2 re-entry (Brugada, Short QT, and Early-Repolarization Syndromes) are evident in the first phase of hyperkalemia. This progresses into a broadening and lengthening of the P wave and PR interval, then eventually disappearance of the P wave, widening of the QRS complex, and finally, asystole.
==== Other milestones (2002–03) ==== For the first three months of the 2002 season, Bagwell labored greatly with throwing; he still had not fully recovered from offseason shoulder surgery. Even after the shoulder improved, it was noticeably weaker than two years prior. In July, he batted .349 with six home runs and 23 RBI. Before a game against the San Diego Padres on August 27, he met with an 11-year-old bone cancer patient named Stephen Rael who asked him to hit a home run for him. Bagwell replied, "I'm going to try, but I'm not Babe Ruth." In the fifth inning, he hit a pitch from Mike Bynum over the left field wall and pointed to the child in the stands as he rounded third base. He later said, "I hit the home run, and he felt it was for him. I'm glad for that. It made it special." From August 10–24, Bagwell produced a season-high 15-game hitting streak, marking the 12th consecutive season with at least one double-digit hit streak, a club record, and second to Roberto Alomar with 14 among all then-active players. In September, he batted .343 with 11 multiple-hit games. During a 3–2 loss to the Montreal Expos on April 26, 2003, Bagwell's infield single gave him 2,000 hits for his career, joining Biggio as the only Astro to achieve this mark. Bagwell collected the assist for the final out of a combined no-hitter and 8–0 win over the Yankees on June 11. He scooped a ground ball batted from Hideki Matsui and relayed it to Billy Wagner covering first base, the final of a record six pitchers participating in the feat.
ASBMB Avanti Award for Lipid Research (1998) Elected to the American Academy of Arts and Sciences (1999) Heinrich Wieland Prize for Lipid Research (2000) Elected to the National Academy of Sciences (2001) Caledonian Prize from the Royal Society of Edinburgh (2002) Pezcoller-AACR International Award for Cancer Research (2005) Rolf Luft Award of the Karolinska Institute (2009) Pasrow Prize for Cancer Research (2011) Breakthrough Prize in Life Sciences (2013) Jacobaeus Prize for Diabetes Research, from the Karolinska Institute (2013) Elected to the Institute of Medicine of the National Academies (2014) AACR Princess Takamatsu Memorial Lectureship (2015) Ross Prize in Molecular Medicine (2015) Canada Gairdner International Award (2015) Elected to European life sciences academy EMBO (2015) The Association of American Cancer Institutes Distinguished Scientist Award (2015) Thomson Reuter's "The World's Most Influential Scientific Minds 2015". The Wolf Prize in Medicine (2016) The Hope Funds Award of Excellence in Basic Science (2016) Louisa Gross Horwitz Prize (2019) He appeared in the 60 Minutes program "Is sugar toxic?".
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.